These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32250720)

  • 1. Reply to Y. Inagaki et al.
    Abu-Sbeih H; Faleck DM; Dougan M; Wang Y
    J Clin Oncol; 2020 May; 38(15):1749-1750. PubMed ID: 32250720
    [No Abstract]   [Full Text] [Related]  

  • 2. Meaningful Symptoms of Immune Checkpoint Inhibitor Therapy-Related Gastrointestinal Adverse Events in Patients With Inflammatory Bowel Disease.
    Inagaki Y; Azuma K; Nakamura Y; Kouno S; Matsuda Y; Atagi S
    J Clin Oncol; 2020 May; 38(15):1748-1749. PubMed ID: 32250716
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et al.
    Petrelli F; Solinas C
    Thromb Res; 2021 Dec; 208():217-218. PubMed ID: 33810866
    [No Abstract]   [Full Text] [Related]  

  • 4. Authors reply to letter to the editor by Dr Degens et al.
    Bommart S; Pujol JL; Coffy A; Daurès JP; Roch B
    Lung Cancer; 2021 Mar; 153():185. PubMed ID: 33461818
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer-Reply.
    Pinato DJ; Newsom-Davis T; Bower M
    JAMA Oncol; 2020 Apr; 6(4):587-588. PubMed ID: 32077899
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Johnson et al. Regarding Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Chen MS; Spiegel BMR
    Am J Gastroenterol; 2018 Nov; 113(11):1721. PubMed ID: 30214014
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply.
    Wang Z; Zhao Z; Wang J
    JAMA Oncol; 2020 Jul; 6(7):1116-1117. PubMed ID: 32352479
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to the Letter to the Editor of Dr. Pauwels et al.
    Shmidt E; Dulai PS
    Inflamm Bowel Dis; 2019 Apr; 25(5):e58. PubMed ID: 31222305
    [No Abstract]   [Full Text] [Related]  

  • 11. A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Liu L; Xu Q; Lizaso A; Zhang Y
    Lung Cancer; 2020 Dec; 150():254-255. PubMed ID: 33153800
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Soteriadou et al.
    Dave M; Purohit T; Razonable RR; Loftus EV
    Inflamm Bowel Dis; 2014 Feb; 20(2):E5-6. PubMed ID: 24374883
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Letter to the Editor of Dr. Sitkin et al., Regarding "Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome is Another Key to the Pathogenesis of Inflammatory Bowel Disease".
    Daniluk U; Daniluk J; Ciborowski M
    Inflamm Bowel Dis; 2019 Nov; 25(12):e159. PubMed ID: 31560772
    [No Abstract]   [Full Text] [Related]  

  • 14. In Reply.
    Gubbi S; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL; Del Rivero J
    Oncologist; 2021 Jan; 26(1):e192-e193. PubMed ID: 33150998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to Falvey et al.
    D'Haens G; Vermeire S
    Inflamm Bowel Dis; 2013 May; 19(6):E81. PubMed ID: 23615483
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to J. Delyon et al.
    Abu-Sbeih H; Ali FS; Owen DH; Ricciuti B; Naqash AR; Wang Y
    J Clin Oncol; 2019 Dec; 37(36):3564-3565. PubMed ID: 31596634
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Dr. Selinger et al.'s letter.
    Manninen P; Collin P
    J Crohns Colitis; 2013 Dec; 7(12):e715. PubMed ID: 24090906
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Zuo et al.
    Kulnigg-Dabsch S; Gasche C
    Inflamm Bowel Dis; 2013 Oct; 19(11):E85-6. PubMed ID: 23962898
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Comment on "Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis" by Li Y and Liu X.
    Zhao S; Xie Q; Zhao Z
    Inflamm Bowel Dis; 2019 Jun; 25(7):e78-e81. PubMed ID: 30851039
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.